Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on January 10, 2017. The report details a corporate governance action regarding the company's capital structure authorized by the Board of Directors and shareholders.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a change to the Articles of Incorporation.
Material Changes
- Authorized Common Stock: Increased from 100,000,000 shares to 250,000,000 shares.
- Total Authorized Capital Stock: The company is now authorized to issue 270,000,000 shares, comprising 250,000,000 shares of common stock and 20,000,000 shares of preferred stock.
- Effective Date: The amendment was filed with the Secretary of State of Florida and became effective on January 10, 2017.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The increase in authorized shares was determined by the Board to be in the best interests of the Company and its shareholders.
Key Facts for Investor Verification
- Verify the exact number of shares currently outstanding versus the new authorized limit of 250,000,000 common shares.
- Review the full text of the Amendment to the Amended and Restated Articles of Incorporation (Exhibit 3.1) for any additional provisions.
- Confirm whether the increase in authorized shares is intended for immediate issuance or future strategic flexibility.